Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AT-rich interactive domain 2, p110α, p53, and β-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.

Human pathology - 1 Apr 2015

You Jason, Yang Hushan, Lai Yinzhi, Simon Lindsay, Au Jen, Burkart Ashlie L

Abstract excerpt

AT-rich interactive domain 2 (ARID2), catenin (cadherin-associated protein), beta 1, 88kDa (β-catenin), tumor protein 53 (p53), and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110α) mutations are implicated in hepatocellular carcinoma (HCC); and previous work has contributed to thorough molecular characterization of these events. However, studies that assess the impact of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class Ia Phosphatidylinositol 3-Kinase

Share to Immunohistochemistry

Share to Liver Neoplasms

Share to Neoplasm Recurrence, Local

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 25701229
DOI: 10.1016/j.humpath.2015.01.001

Genes

ARID2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AT-rich interactive domain 2, p110α, p53, and β-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications.PMID 25701229Read ↗

ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular MechanismsSemantic proximity Read ↗

ARID2: a new tumor suppressor gene in hepatocellular carcinoma.Semantic proximity Read ↗

Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular CarcinomaSemantic proximity Read ↗

Effect of ARID1A mutation and expression on prognosis of hepatocellular carcinoma and cholangiocarcinoma: a meta-analysisSemantic proximity Read ↗

ARID1A alterations and their clinical significance in cholangiocarcinomaSemantic proximity Read ↗

Evaluation of ATAD2 As a Potential Target in Hepatocellular CarcinomaSemantic proximity Read ↗

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.Semantic proximity Read ↗

ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular CarcinomaSemantic proximity Read ↗

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinomaSemantic proximity Read ↗

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.Semantic proximity Read ↗

The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.